LEADER 02086oam  2200469I  450 
001 9910159439903321
005 20230810001724.0
010   $a1-315-31458-4
010   $a1-315-31460-6
010   $a1-315-31459-2
024 7 $a10.1201/9781315314600 
035   $a(CKB)3710000001018997
035   $a(MiAaPQ)EBC4786523
035   $a(OCoLC)968706275
035   $a(EXLCZ)993710000001018997
100   $a20180331h20172017  uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aIntroduction to market access for pharmaceuticals /$fMondher Toumi
210  1$aBoca Raton, FL :$cCRC Press,$d[2017]
210  4$dİ2017
215   $a1 online resource (204 pages) $cillustrations, tables
311   $a1-138-45705-1 
311   $a1-138-03218-2 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $achapter 1. Health as a good -- chapter 2. Decision-making in public health -- chapter 3. Definitions and concepts -- chapter 4. HTA decision analysis framework -- chapter 5. Early HTA advice -- chapter 6. Overview of market access agreements -- chapter 7. External reference pricing -- chapter 8. Gap between payers and regulators -- chapter 9. Early access programs -- chapter 10. Market access of orphan drugs -- chapter 11. Market access of vaccines in developed countries -- chapter 12. France -- chapter 13. Germany -- chapter 14. Italy -- chapter 15. Spain -- chapter 16. Sweden -- chapter 17. United Kingdom -- chapter 18. Belgium -- chapter 19. The United States -- chapter 20. Japan -- chapter 21. China.
606   $aPharmaceutical industry
606   $aMarketing
615  0$aPharmaceutical industry.
615  0$aMarketing.
676   $a338.476151
700   $aToumi$b Mondher$0870969
702   $aToumi$b Mondher
801  0$bFlBoTFG
801  1$bFlBoTFG
906   $aBOOK
912   $a9910159439903321
996   $aIntroduction to market access for pharmaceuticals$91944284
997   $aUNINA